We are pleased to announce the election of Paula to our Board of Directors,” said Rodney A. Young, president and CEO of Angeion. “Paula’s experience in the health care industry and her expertise in product launches and commercialization make her a valuable asset to our board.”

“I am extremely honored to join Angeion’s Board of Directors,” said Skjefte. “Angeion has a proven record of success – including five consecutive years of double-digit growth – and its leading-edge core cardiorespiratory technology and market growth opportunities, both domestically and internationally, suggest a productive future.”

Skjefte brings more than 25 years of health care experience to Angeion. While at Medtronic, Inc. she held a number of roles, including vice president of consumer business for the physio control division and vice president of marketing, product and strategic planning in the arrhythmia management division. As a vice president at Medtronic, Skjefte helped create the first consumer AED business, led strategic and product planning goals and worldwide marketing efforts and chaired the Cardiac Rhythm Management Product Portfolio Board. Skjefte previously served on the boards of the Medtronic Foundation, Vitatron Corporation, Medtronic European and Japanese Operating and is a member of the National Association of Corporate Directors. She earned an MBA from the University of Minnesota and a bachelor of science in nursing degree from the University of Wisconsin.

About Angeion Corporation

Founded in 1986, Angeion Corporation acquired Medical Graphics Corporation in December 1999. Medical Graphics develops, manufactures and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics (www.medgraphics.com) and New Leaf Fitness (www.newleaffitness.com) brand and trade names. These cardiorespiratory diagnostic systems have a wide range of applications in healthcare as well as health and fitness. The Company’s products are sold internationally through distributors and in the United States through a direct sales force that targets heart and lung specialists located in hospitals, university-based medical centers, medical clinics and physicians’ offices, pharmaceutical companies, medical device manufacturers, clinical research organizations, health and fitness clubs, personal training studios, and other exercise facilities. For more information about Angeion, visit www.angeion.com.

The discussion above contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements by their nature involve substantial risks and uncertainties. Actual results may differ materially depending on a variety of factors, including (i) the Company’s ability to successfully operate its business including its ability to develop, improve, and update its cardiorespiratory diagnostic products, (ii) the Company’s ability to effectively manufacture and ship its products in anticipated required quantities to meet customer demands, (iii) the Company’s ability to successfully defend itself from product liability claims related to its cardiorespiratory diagnostic products and claims associated with its prior cardiac stimulation products, (iv) the Company’s ability to protect its intellectual property, and (v) the Company’s dependence on third-party vendors. Additional information with respect to the risks and uncertainties faced by the Company may be found in, and any prior discussion is qualified in its entirety by, the other risk factors that are described from time to time in Angeion's Securities and Exchange Commission reports, including but not limited to the Annual Report on Form 10-KSB for the year ended October 31, 2005, and subsequently filed reports.